Source:Vaccine, Volume 35, Issue 29
Author(s): Wendi Wu, Dawei Liu, Keli Li, J. Pekka Nuorti, Hanna M. Nohynek, Disha Xu, Jiakai Ye, Jingshan Zheng, Huaqing Wang
IntroductionTwo types of Japanese encephalitis (JE) vaccines, inactivated JE vaccine (JE-I) and live-attenuated JE vaccine (JE-L), are available and used in China. In particular, one JE-L, produced by a domestic manufacturer in China, was prequalified by WHO in 2013. We assessed the safety of JE vaccines in China during 2008–2013 using the Chinese National Adverse Events Following Immunization Information System (CNAEFIS) data.MethodsWe retrieved AEFI reporting data about JE vaccines from CNAEFIS, 2008–2013, examined demographic characteristics of AEFI cases, and used administrative data on vaccine doses as denominator to calculate and compare crude reporting rates. We also used disproportionality reporting analysis between JE-I and JE-L to assess potential safety signals.ResultsA total of 34,879 AEFIs related with JE-I and JE-L were reported, with a ratio of male to female as 1.3:1; 361 (1.0%) cases were classified as serious. JE vaccines were administered concurrently with one or more other vaccines in 13,592 (39.0%) of cases. The overall AEFI reporting rates were 214.4 per million vaccination doses for JE-L and 176.9 for JE-I (rate ratio [RR]: 1.2, 95% confidence interval [CI]: 1.1–1.3) in 2010–2013. Febrile convulsions (FC) following JE-I was found as a signal of disproportionate reporting (SDR). However, there was no significant difference between the reporting rates of FC of JE-I and JE-L (0.3 per million vaccination doses for JE-L, 0.4 for JE-I, p=0.05).ConclusionsWhile our analysis did not find apparent safety concern of JE vaccines in China, further study should consider JE-I vaccines and febrile convulsion, and taking more sensitive methods to detect signals.
http://ift.tt/2rkGMdd
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου